Raynaud’s phenomenon is a condition characterised by episodic vasospasm of the arteries, primarily affecting the fingers and toes, triggered by cold, smoking, medicines (b-blockers) or emotional stress. Raynaud’s phenomenon manifests as a progression through pallor, cyanosis and erythema as blood flow alters. While primary Raynaud’s phenomenon is much more common, occurs in isolation and is generally benign, secondary Raynaud’s phenomenon is often associated with underlying autoimmune or connective tissue diseases such as systemic sclerosis (scleroderma), systemic lupus erythematosus or mixed connective tissue disease. Identifying secondary Raynaud’s phenomenon is crucial, as it signals more severe pathology requiring prompt intervention. Raynaud’s phenomenon comes with various diagnostic and management challenges, including failure to differentiate primary from secondary Raynaud’s, underutilisation of nailfold capillaroscopy and misdiagnosis in the context of other rheumatic diseases. Inadequate evaluation of clinical findings, autoantibodies and systemic involvement often delays the recognition of conditions like scleroderma and mixed connective tissue disease. Insufficient treatment, particularly in secondary Raynaud’s phenomenon, can lead to digital ulcers, ischaemic tissue damage and eventually gangrene of the affected digit/toe. A comprehensive evaluation, including nailfold capillaroscopy and autoantibody testing, pharmacologic treatment and monitoring for complications are needed.